Thromboembolic Events

Lee JJ, Pope JE. A meta-analysis of the risk of venous thromboembolism in inflammatory rheumatic diseases. Arthritis Research & Therapy. 2014.25;16(5):435.

Springer J, Villa-Forte A. Thrombosis in vasculitis. Current Opinion in Rheumatology. 2013;25(1):19–25.

Johannesdottir SA, Schmidt M, Horváth-Puhó E et al. Autoimmune skin and connective tissue diseases and risk of venous thromboembolism: a population‐based case‐control study. Journal of Thrombosis and Haemostasis. 2012;10(5):815–21.

Alghareeb R, Hussain A, Maheshwari M V, et al. Cardiovascular Complications in Systemic Lupus Erythematosus. Cureus. 2022;14(7): e26671.

Fatoye F, Gebrye T, Mbada C. Global and regional prevalence and incidence of systemic lupus erythematosus in low-and-middle income countries: a systematic review and meta-analysis. Rheumatology International. 2022;42(12):2097–107.

Lee J, Dhillon N, Pope J. All-cause hospitalizations in systemic lupus erythematosus from a large Canadian referral centre. Rheumatology. 2013;52(5):905–9.

Belizna C. Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome. Autoimmunity Reviews. 2015;14(4):358–62.

Fanouriakis A, Kostopoulou M, Alunno A et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Annals of the Rheumatic Diseases. 2019;78(6):736–45.

Unlu O, Zuily S, Erkan D. The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus. European Journal of Rheumatology. 2016;3(2):75–84.

Duarte‐García A, Pham MM, Crowson CS et al. The Epidemiology of Antiphospholipid Syndrome: A Population‐Based Study. Arthritis & Rheumatology. 2019;71(9):1545–52.

Konstantinides S, Meyer G, Becattini C et al. Guía ESC 2019 para el diagnóstico y tratamiento de la embolia pulmonar aguda. Revista Española de Cardiología. 2020;73(6):497.e1-497.e58.

Tektonidou MG, Andreoli L, Limper M et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Annals of the Rheumatic Diseases. 2019;78(10):1296–304.

Cáliz Cáliz R, Díaz del Campo Fontecha P, Galindo Izquierdo M et al. Recomendaciones de la Sociedad Española de Reumatología sobre síndrome antifosfolípido primario. Parte I: Diagnóstico, evaluación y tratamiento. Reumatología Clínica. 2020;16(2):71–86.

Sciascia S, Sanna G, Murru V et al. The global anti-phospholipid syndrome score in primary APS. Rheumatology. 2015;54(1):134–8.

Garcia D, Akl EA, Carr R et al. Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review. Blood. 2013;122(5):817–24.

Pengo V, Hoxha A, Andreoli L et al. Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two‐year outcomes after the study closure. Journal of Thrombosis and Haemostasis. 2021;19(2):531–5.

Baiazid L, Hraib M. Effects of low-dose aspirin and heparin on the pregnancy outcome in women with antiphospholipid syndrome. Annals of Medicine & Surgery (Lond). 2022;83:104807.

Papadakis E, Banti A, Kioumi A. Women’s Issues in Antiphospholipid Syndrome. Israel Medical Association Journal. 2016;18(9):524–9.

Royal College of Obstetricians and Gynaecologists. Royal college of obstetricians and gynaecologists. Reducing the risk of thrombosis and embolism during pregnancy and the puerperium. RCOG Green-top Guideline. 2015. No 37a.

Díaz-Coronado JC, Herrera-Uribe S, Hernández-Parra D et al. Síndrome antifosfolípido (SAF): diferencias clínicas e inmunoserológicas entre SAF primario y secundario en una cohorte colombiana. Revista Colombiana de Reumatología. 2021;28(3):191–6.

Hu LJ, Ji B, Fan HX. Venous thromboembolism risk in rheumatoid arthritis patients: a systematic review and updated meta-analysis. European Review for Medical and Pharmacological Sciences. 2021;25(22):7005–13.

Mameli A, Barcellona D, Marongiu F. Rheumatoid arthritis and thrombosis. Clinical and Experimental Rheumatology. 2009;27(5):846–55.

Li L, Lu N, Avina-Galindo AM et al. The risk and trend of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a general population-based study. Rheumatology. 2021.5;60(1):188–95.

Kang JH, Keller JJ, Lin YK et al. A population-based case-control study on the association between rheumatoid arthritis and deep vein thrombosis. Journal of Vascular Surgery. 2012;56(6):1642–8.

Chung WS, Peng CL, Lin CL et al. Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study. Annals of the Rheumatic Diseases. 2014;73(10):1774–80.

Ogdie A, Kay McGill N, Shin DB et al. Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study. European Heart Journal. 2018.14;39(39):3608–14.

Petitpain N, Gambier N, Wahl D et al. Arterial and venous thromboembolic events during anti-TNF therapy: A study of 85 spontaneous reports in the period 2000–2006. Biomedical Materials and Engineering. 2009;19(4–5):355–64.

Kim KJ, Baek IW, Park KS et al. Association between antiphospholipid antibodies and arterial thrombosis in patients with rheumatoid arthritis. Lupus. 2017.20;26(1):88–94.

Choi HK, Rho YH, Zhu Y et al. The risk of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a UK population-based outpatient cohort study. Annals of the Rheumatic Diseases. 2013;72(7):1182–7.

Zervou MI, Goulielmos GN. Comment on: The risk and trend of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a general population-based study. Rheumatology. 2021. 1;60(7):e266–7.

Ketfi C, Boutigny A, Mohamedi N et al. Risk of venous thromboembolism in rheumatoid arthritis. Joint Bone Spine. 2021;88(3):105122.

Gaffo AL. Thrombosis in vasculitis. Best Practice & Research Clinical Rheumatology. 2013;27(1):57–67.

Fei Y, Li X, Lin S et al. Major vascular involvement in Behçet’s disease: a retrospective study of 796 patients. Clinical Rheumatology. 2013.27;32(6):845–52.

Ulusan Z, Karadag AS, Tasar M et al. Behcet’s disease and cardiovascular involvement : our experience of asymptomatic Behcet’s patients : cardiovascular topic. Cardiovascular Journal of Africa. 2014;25(2):63–6.

Bettiol A, Alibaz-Oner F, Direskeneli H et al. Vascular Behçet syndrome: from pathogenesis to treatment. Nature Reviews Rheumatology. 2023;19(2):111–26.

Silvestri E, Emmi G, Prisco D. Vascular Behçet’s disease: new insights in the management of thrombosis. Expert Review of Cardiovascular Therapy. 2013;11(12):1583–5.

Islam MA, Alam SS, Kundu S et al. Prevalence of antiphospholipid antibodies in Behçet’s disease: A systematic review and meta-analysis. PLoS One. 2020;15(1):e0227836.

Hatemi G, Silman A, Bang D et al. EULAR recommendations for the management of Behçet disease. Annals of the Rheumatic Diseases. 2008;67(12):1656–62.

Balta I, Balta S, Koryurek OM et al. Mean platelet volume is associated with aortic arterial stiffness in patients with Behçet’s disease without significant cardiovascular involvement. Journal of the European Academy of Dermatology and Venereology. 2014;28(10):1388–93.

Rhee MY, Chang HK, Kim SK. Intima-media Thickness and Arterial Stiffness of Carotid Artery in Korean Patients with Behçet’s Disease. Journal of the Korean Medical Sciences. 2007;22(3):387.

Desbois AC, Wechsler B, Resche-Rigon M et al. Immunosuppressants reduce venous thrombosis relapse in Behçet’s disease. Arthritis & Rheumatology. 2012;64(8):2753–60.

Faurschou M, Obel N, Baslund B. High Risk of Pulmonary Embolism and Deep Venous Thrombosis but Not of Stroke in Granulomatosis With Polyangiitis (Wegener’s). Arthritis Care & Research (Hoboken). 2014;66(12):1910–4.

Ungprasert P, Srivali N, Kittanamongkolchai W. Risk of venous thromboembolism in patients with Sjögren’s syndrome: a systematic review and meta-analysis. Clinical and Experimental Rheumatology. 2015;33(5):746–50.

Ungprasert P, Srivali N, Wijarnpreecha K et al. Sarcoidosis and risk of venous thromboembolism: A systematic review and meta-analysis. Sarcoidosis Vascular Diffuse Lung Disease. 2015. 14;32(3):182–7.